PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33074119-1	2020	Herein, we report the synthesis of novel 2-substituted styrylquinazolines conjugated with aniline or sulfonamide moieties, anticipated to act as potent anticancer therapeutic agents through preferential EGFR inhibition.	aniline	90-97	epidermal growth factor receptor	Homo sapiens	203-207	
24269511-4	2014	SAR and docking studies allowed the identification of pharmacophoric groups for both kinases and demonstrated the importance of a hydrogen bond donor at the para position of the aniline moiety for interaction with conserved Glu and Asp amino acids in EGFR and VEGFR-2 binding sites.	aniline	178-185	epidermal growth factor receptor	Homo sapiens	251-255	
27983649-1	2016	Sixteen novel epidermal growth factor receptor (EGFR)/vascular endothelial growth factor (VEGF)-2 inhibitors (nitroimidazole-substituted 4-anilinoquinazoline derivatives (16a-p)) were designed and prepared via the introduction of a nitroimidazole group in the piperidine side chain and modification on the aniline moiety of vandetanib.	aniline	306-313	epidermal growth factor receptor	Homo sapiens	14-46	
27102572-8	2016	Analysis of substituent patterns suggested that EGFR-inhibitors with small aniline substituents in the 4-position of the quinazoline ring were more effective than inhibitors with large substituents in that position.	aniline	75-82	epidermal growth factor receptor	Homo sapiens	48-52	
26829280-1	2016	With the aim of overcoming gefitinib resistance, a series of novel quinazoline derivatives bearing an adamantyl group on the aniline ring were synthesized as potent epidermal growth factor receptor (EGFR) inhibitors.	aniline	125-132	epidermal growth factor receptor	Homo sapiens	165-197	
26829280-1	2016	With the aim of overcoming gefitinib resistance, a series of novel quinazoline derivatives bearing an adamantyl group on the aniline ring were synthesized as potent epidermal growth factor receptor (EGFR) inhibitors.	aniline	125-132	epidermal growth factor receptor	Homo sapiens	199-203	
25305687-1	2014	The interactions of gefitinib (Iressa) in EGFR are hydrogen bonding and van der Waals forces through quinazoline and aniline rings.	aniline	117-124	epidermal growth factor receptor	Homo sapiens	42-46	
22867529-1	2013	We report here the design and synthesis of a series of 4-anilinoquinazoline derivatives, of which 7 compounds were crystallographically characterized, as epidermal growth factor receptor (EGFR) inhibitors by modifications on the aniline ring or at the 6-alkoxy site of the 6,7-dimethoxy-4-anilinoquinazoline pharmacophore.	aniline	229-236	epidermal growth factor receptor	Homo sapiens	154-186	
22867529-1	2013	We report here the design and synthesis of a series of 4-anilinoquinazoline derivatives, of which 7 compounds were crystallographically characterized, as epidermal growth factor receptor (EGFR) inhibitors by modifications on the aniline ring or at the 6-alkoxy site of the 6,7-dimethoxy-4-anilinoquinazoline pharmacophore.	aniline	229-236	epidermal growth factor receptor	Homo sapiens	188-192	
21177105-1	2011	A novel series of 5-((4-aminopiperidin-1-yl)methyl)-pyrrolo[2,1-f][1,2,4]triazin-4-amines with small aniline substituents at the C4 position were optimized for dual EGFR and HER2 protein tyrosine kinase inhibition.	aniline	101-108	epidermal growth factor receptor	Homo sapiens	165-169	
19208477-0	2009	Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors.	aniline	28-35	epidermal growth factor receptor	Homo sapiens	81-85	
19208477-1	2009	Aniline "headgroups" were synthesized and incorporated into an alkynyl thienopyrimidine series of EGFR and ErbB-2 inhibitors.	aniline	0-7	epidermal growth factor receptor	Homo sapiens	98-102